Clinical Trials in Netherlands

• DALY 2-EU Ended
  2023-506270-13-00 Phase II Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL… Miltenyi Biomedicine GmbH
• NADINA Ended
  2024-513519-28-00 Phase III Stage III melanoma Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Induction chemotherapy for locally advanced rectal cancer. Ended
  2023-509758-74-00 Phase II Locally advanced rectal cancer Catharina Ziekenhuis Stichting
• A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Ended
  2023-506585-31-00 Phase I Metastatic castration-resistant prostate cancer Janssen - Cilag International
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination with other Anti-Cancer Therap… Ended
  2023-506311-18-00 Phase I Advanced or metastatic solid tumors with KRAS G12C mutation Genentech Inc.
• A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended
  2022-502100-70-00 Phase II/III Participants with Microsatellite Instability-High (MSI-H) or… Merck Sharp & Dohme LLC
• Efficacy and Safety Comparison of Niraparib to Placebo in Participants with HER2 Negative BRCAmut or Triple-Negative Breast Cancer with Mole… Ended
  2023-504454-35-00 Phase III Neoplasms, Breast Glaxosmithkline Research & Development Limited
• PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therap… Ended
  2023-507772-50-00 Phase III PSMA-positive metastatic castration-resistant prostate cance… Novartis Pharma AG
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended
  2023-504684-16-00 Phase III follicular lymphoma (FL) and marginal zone lymphoma (MZL) Incyte Corp.
• A study to evaluate the safety and tolerability of seladelpar in subjects with primary biliary cholangitis Ended
  2024-511753-22-00 Phase III Primary Biliary Cholangitis Gilead Sciences Inc.
• A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St… Ended
  2023-508372-10-00 Phase II Non small Cell Lung cancer Bristol-Myers Squibb Services Unlimited Company
• DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Ended
  2023-509865-19-00 Phase III Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Daiichi Sankyo Inc.
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended
  2023-507961-24-00 Phase III High-Risk HER2-Positive Breast Cancer Daiichi Sankyo Inc.
• A research study to find out if the study treatment alpelisib (BYL719) is safe and can help others who have confirmed diagnosis of PIK3CA-re… Ended
  2023-508530-34-00 Phase II PIK3CA-Related Overgrowth Spectrum (PROS) Novartis Pharma AG
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended
  2024-510620-39-00 Phase III Advanced RCC with clear cell component Merck Sharp & Dohme LLC
• A Study to Evaluate the Efficacy and Safety of Crovalimab versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemog… Ended
  2023-506498-36-00 Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) F. Hoffmann-La Roche AG
• Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexande… Ended
  2024-510603-11-00 Phase I (FiH) Alexander Disease Ionis Pharmaceuticals Inc.
• A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac… Ended
  2024-514467-26-00 Phase II Indolent Systemic Mastocytosis Telios Pharma Inc.
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended
  2023-507970-42-00 Phase III PSMA-positive metastatic hormone-sensitive prostate cancer (… Novartis Pharma AG
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended
  2023-506962-30-00 Phase III Non-alcoholic steatohepatitis (NASH) Novo Nordisk A/S
• A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto… Ended
  2023-503916-33-00 Phase III Diffuse Large B-Cell Lymphoma (DLBCL) ADC Therapeutics S.A.
• A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemo… Ended
  2023-506526-37-00 Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) F. Hoffmann-La Roche AG
• A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine ( REBUILD-2 ) Ended
  2023-505835-11-00 Phase III Chronic Migraine Eli Lilly & Co.
• A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine ( REBUILD-1 ) Ended
  2023-505836-36-00 Phase III Migraine Eli Lilly & Co.

Showing 1,105–1,128 of 1,869 trials